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ABSTRACT
Objective: Verifying the evidence of therapeutic efficacy in the topical application of 
metronidazole for controlling wound odor. Methods: A systematic literature review, 
according to the Cochrane Collaboration recommendations. Results: 329 articles were 
identified in the Cochrane, LILACS, SciELO, CINAHL and PubMed databases, with 
14 of them being included in the final sample. Two of the studies were double-blind 
randomized clinical trial studies. Conclusion: The actual effectiveness of metronidazole 
in controlling wound odor cannot yet be evidenced due to the absence of strong evidence 
from studies on the subject, despite clinical practice recommending its benefits.
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INTRODUCTION
Colonization and bacterial infection are factors that in-
terfere with wound healing, especially in chronic wounds. 
To control these factors, antiseptics and topical antibiotics 
are accepted as the best option for local infection treatment 
(in some cases the use of systemic antibiotics is necessary). 
Infection in wounds slows the healing process and may have 
systemic complications if not quickly controlled(1).
Unpleasant odor is a common and distressing concern 
for people with infected wounds, as well as for their family 
members and caregivers. Patients with fetid wounds often 
experience social isolation, depression, shame, embarrass-
ment and lack of appetite, factors that can have a nega-
tive impact on their quality of life. Nurses who treat these 
patients face difficult clinical challenges when treating the 
cause and controlling the symptoms(2).
Wound odor is not only experienced by patients under 
palliative care, it is also perceived in chronic leg wounds and 
pressure ulcers. Wound necrosis contributes to the occur-
rence of odor, but it cannot be perceived as the main cause 
of its emergence(3).
There are several silver-based, iodine-based, honey-
based and topical antibiotic products available to help odor 
control. Among topical antibiotics, metronidazole has been 
described as effective in controlling wound odor. Metro-
nidazole is a nitroimidazole derivative with antiprotozoal 
action. It also has bactericidal activity against gram-negative 
anaerobic bacilli, all sporulated anaerobic cocci and gram-
positive bacilli. Putrid odor is characteristic of local infec-
tion by anaerobic bacteria, which justifies its action and use 
for odor control(2).
Thus, we aimed to verify the evidence of therapeutic effica-
cy in using topical metronidazole for controlling wound odor.
METHOD
We performed a systematic literature review (SR) on 
the use of metronidazole as topical wound therapy for odor 
control of any etiology according to the recommendations 
of the Cochrane Collaboration(4). For this purpose, we in-
cluded studies published in the Cochrane, LILACS, CI-
NAHAL, SciELO and PubMed databases, until December 
2014. Descriptors indexed on MeSH and DeCS databases 
were used according to PICO – Patient, Intervention, Com-
parison, and Outcome(4) electronic search methodology:
For the selection and inclusion of articles in the sys-
tematic review (SR), the following criteria were defined: 
studies in which (human) wounds were topically treated 
with metronidazole; published in full; published in na-
tional and international journals indexed in the estab-
lished databases, and without language barrier.
Data collection was carried out in the 1st semester of 
2015 by electronic search (internet) without data restric-
tion, performed on each of the five selected databases. 
All studies retrieved consistent with the research strategy 
were evaluated according to the title and abstract by two 
independent researchers. Even in cases where data were 
not sufficient, studies were included in pre-selection, 
thereby avoiding erroneous deletions. After the studies 
were obtained in full, they had their references checked, 
in order to recover possible studies not yet verified. Data 
were collected during full article readings, through a 
specific instrument containing: title, journal, year, main 
author, type of study, solution used.
Data were analyzed in three stages:
Phase 1 – Characterization of the selection process of 
studies: analysis of data concerning the total number of 
studies recovered by databases. After searching the da-
tabases, two different researchers individually analyzed 
the retrieved articles (by title and abstract) and identified 
articles relevant to the proposed theme – metronidazole 
in wounds. Studies to be read in full and those which 
would be included in the SR were selected by consensus.
Phase 2 – Characterization of included studies: analysis 
of data related to included studies by two researchers, 
such as title, journal, year, main author, study type, ap-
plication method, concentration of metronidazole and 
outcome.
Phase 3 – Quality assessment and evidence of the in-
cluded studies: studies had their quality (internal valid-
ity) assessed according to STROBE – Strengthening the 
Reporting of Observational studies in Epidemiology for 
observational studies(5) and CONSORT – Consolidated 
Standards of Reporting Trials for clinical trials(6) (case re-
ports do not have internal quality evaluation).
For STROBE evaluation, each of the 22 criteria re-
ceived a score from 0 to 1 (0 - described and 1 - not 
described). For evaluation according to CONSORT, also 
consisting of 22 items, scores were performed considering 
0 - not described, 1 - partially described and appropriate 
and 2 - appropriate (in cases where not applicable, such 
as in uncontrolled clinical studies, items were not added). 
The total score was converted into percentages for better 
P
“Deiscência da Ferida Operatória – Surgical Wound 
Dehiscence” OR “Ferimentos e Lesões – Wounds and 
Lesions” OR “Ferimentos Penetrantes – Penetrating 
Wounds” OR “Infecção da Ferida Operatória – Surgical 
Wound Infection” OR “Cicatrização – Healing” 
OR “Úlcera Cutânea – Skin Ulcer” OR “Úlcera por 
Pressão – Pressure Ulcer” OR “Pé Diabético – Diabetic 
foot (infection)” OR “Úlcera do Pé – Foot Ulcer” OR 
“Úlcera Varicosa – Varicose Ulcer” OR “Úlcera da Perna 
– Leg Ulcer” OR “Infecção dos Ferimentos – Wound 
infections” OR “Infecções Bacterianas e Micoses – 
Bacterial infections and Mycoses” OR “Infecções por 
Bactérias Gram-Negativas – Gram-Negative Bacterial 
Infections” OR “Infecções por Bactérias Gram-Positivas 
– Gram-Positive Bacterial Infections”
continued...
...continuation
I
“Metronidazole” OR “Nitroimidazóis - 
Nitroimidazoles” OR “Anti-Infecciosos – Anti-Infection” 
OR “Antibacterianos – Antibacterial”
C No comparison.
O
“Neutralizadores de Odores – Odor neutralization” 
OR “Odores – Odors” OR “Desodorização – 
Deodorization”
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article evaluation. Items that reached a percentage higher 
than 70% were considered of good quality.
RESULTS
Research showed that there were no systematic reviews on 
the use of metronidazole in wound odor control. 26 studies 
were pre-selected, one study in animals and 6 studies per-
formed by other means of administration of metronidazole 
(three orally, one intravenously and two studies did not de-
scribe the method of administration) and four review studies 
were excluded (Figure 1). Among the three letters to the editor 
identified, one describes a randomized clinical trial, but there 
was not enough data for study evaluation, so it was then de-
leted. 14 articles were included in the study (Chart 1).
Retrived from database
Total = 329
Lilacs
25
Pubmed
151
Cinahl
142
Cochrane
3
Scielo
8
Pre-selected
26
Included
14
Clinical Trial
6
Case Report
4
Descriptive
2
Letter to the Editor
2
Figure 1 – Description of the strategy carried out for the search and inclusion of articles – São Paulo, SP, Brazil, 2015. 
Chart 1 – Description of the 14 studies identified on the use of metronidazole in wounds for odor control – São Paulo, SP, Brazil, 2015.
Author, year Sample Intervention Application Wound type Outcome for odor control
Letter to the Editor
Jones,         1978(7)
Not reported.
Case report.
Metronidazole 1% 
solution, autoclaved 
at 121ºC for 20 
minutes.
Dampened gauze.
Pressure ulcers, 
diabetic ulcers, 
venous ulcers 
and abscesses.
Odor reduction in a few hours. 
Odorless in 24 hours, wounds clean 
and free of anaerobic bacteria and 
cellulite.
- No statistical result.
Ashford, 1984(8)
12 patients.
Randomized, 
double-blind 
case study.
Comparison 
of two groups: 
metronidazole 
200mg 3 times a day 
versus placebo.
Does not describe 
administration and 
application.
Malignant 
neoplastic 
wound.
Experimental group had odor 
reduction (p<0.01), and reduction of 
microbial load (p < 0.005).
CONSORT: 42%
Case report
Ashford, 1980(9) 1 patient Metronidazole 200 mg 3 times a day.
Does not describe 
the form of 
administration or 
application.
Malignant 
neoplastic 
wound.
Odor reduction in 1 week.
Gomolin, 1983(10) 4 patients Metronidazole 1% solution.
Moistened gauze, 
changed every 8h.
Pressure ulcers in 
stages II to IV. Odor reduction from 48 hours to 1 week.                                                   
Pierleoni, 1984(11) 2 patients Metronidazole 1% solution. 
Moistened gauze, 
changed every 8h.
Pressure ulcers in 
stages III and IV. High reduction in odor control. 
Burnakis, 1989(12) 1 patient
Metronidazole 1% 
solution, autoclaved 
at 121ºC for 20 
minutes.
10 ml of solution 
was applied to 
gauze at each 
shift. After the 
gauze dried, it 
was removed, 
"warm light" was 
applied for 20 to 30 
minutes.
Pressure ulcer 
(stage was not 
described).
Odor reduction in 24 to 48 hours.
 
continued...
854 Rev Esc Enferm USP · 2015; 49(5):851-856 www.ee.usp.br/reeusp
Controlling wound odor with metronidazole: a systematic review
...continuation
Author, year Sample Intervention Application Wound type Outcome for odor control
Descriptive
Witkowski1, 
1991(13) 10 patients
Metronidazole gel 
(without description 
of concentration).
Soak with 
saline solution, 
application of a 
thin layer of gel 
covered with 
gauze. Changed 
every 12 hours.
Sacral pressure 
ulcer stages III 
to IV.
Odor elimination of all wounds in 
36 hours.
- No statistical results.
STROBE: 46%
McMullen, 
1992(14) 11 patients
Metronidazole 
0.75%  gel in 
wounds and 1% 
solution for fistulas
Applied 1 or 2 
times a day.
Malignant 
neoplastic 
wound, 
Radiodermatitis, 
fistula and 
pressure ulcer.
After 24 hours the odor was noticed 
only at bandage opening/removal; in 
5 days odor was eliminated.
- No statistical results.
STROBE: 61%
Clinical Trial
Newman,
1989(15) 68 patients 
Metronidazole 0.8% 
gel 
Application of 
metronidazole 
gel covered with 
gauze. Changed 
once a day.
Not described, 
only mentions 
that wounds are 
fetid.
Odor reduction in 96% of the 
subjects, where 50% were total 
control and 46% were partial 
control.
- No statistical results.
CONSORT: 62%
Bower, 1992(16) 9 patients
Comparison 
of two groups: 
metronidazole 0.8% 
gel versus placebo.
Placebo or 
metronidazole 
gel applied once 
a day for 5 days, 
followed by 6 days 
of metronizadole.
Malignant 
neoplastic 
wound.
Odor reduction in 5 days for 
experimental group (p < 0.001). 
CONSORT: 71%
Finlay, 1996(17) 39 patients Metronidazole 0.75%  gel.
Application 
of gauze with 
metronidazole gel.
Neoplastic 
wounds and leg 
ulcers.
Odor reduction with metronidazole 
(p < 0.002).
CONSORT: 84%
Kuge, 1996(18) 5 patients
Comparison 
of two groups: 
metronidazole 0.8% 
gel versus placebo.
Applied 1 or 2 
times a day.
Wounds caused 
by breast cancer.
Odor reduction or elimination from 
2 to 5 days in the experimental 
group.
- No statistical results.
CONSORT: 65%
Bale, 2004(2) 41 patients
Comparison 
of two groups: 
metronidazole 0.8% 
gel versus placebo.
1 application once 
a day.
Arterial, venous, 
dehiscence and 
pressure ulcer.
100% reduction for group with 
metronidazole versus 76% placebo 
(p<0.05). 
CONSORT: 68%
Kalinski, 2005(19) 16 patients Metronidazole 0.75% gel.
Applied 1 or 2 
times a day.
Neoplastic 
wounds.
100% odor reduction.
CONSORT: 73%
DISCUSSION
In 1978(7), one study reported (in the form of a letter 
to the editor) the putrid odor that some pressure ulcers ex-
uded and other cases in which patients progressed to sep-
sis caused by anaerobic bacteria. The authors describe that 
from previous publications on the successful treatment of 
patients with sepsis caused by anaerobic bacteria through 
systemic metronidazole, they began to suggest its topical 
use on infected wounds. In the same report, the authors 
mention that there was a lack of topical formulations at 
that time, therefore the hospital pharmacy manipulated a 
metronidazole 1% solution, and applied it to pressure ul-
cers, diabetic ulcers, leg ulcers and venous ulcers with odor, 
through moistened gauze. As the outcome, there was odor 
reduction from the wounds within a few hours, in addi-
tion to there being negative cultures on the surface of the 
wounds after 24 hours.
In 1980, other authors(9) proposed the use of metronida-
zole for odor control in neoplastic wounds for the first time, 
to publish a case report in which the wound had offensive 
and putrid odor – characteristic of infection by anaerobes. 
They proposed a local treatment with 200 mg of metroni-
dazole three times a day, with no description of the form 
of administration (oral, intravenous or topical). They found 
odor reduction in a week, which they only noticed when 
they removed the dressing and it was less offensive than 
before. According to the authors, the patient returned to 
work as a teacher, noting that this would be unlikely in 
the previous condition, improving their quality of life and 
without any toxicity.
Currently, topical metronidazole is recommended for 
wounds to control odor through its action on anaerobic 
bacteria responsible for producing volatile acids, which 
cause the odor, without the side effects of oral use(19). Topi-
cal application of metronidazole has little or no systemic 
absorption(20).
According to this review, topical wound therapy uses 
metronidazole solution in 0.75 and 0.8%, in the form of a 
gel or liquid. However, some authors describe its application 
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by macerating oral tablets with subsequent dilution; others 
only describe that it was manipulated without detailing how 
this was done, and others describe the use of Metrotop® 
(metronidazole 0.8% gel not available in Brazil). No in-
struments for the evaluation of odor have been identified, 
which compromises the interpretation of results when this 
is described as odor reduction.
Despite being identified in only two randomized clini-
cal trials on topical metronidazole therapy for wounds, the 
results showed different outcomes (making it impossible to 
conduct meta-analysis). Clinical experience suggests that 
metronidazole is effective in odor control, especially in neo-
plastic (cancer) wounds(19).
In Brazil, metronidazole is available in the form of vaginal 
cream (8% - 400mg/5g and 10% - 500mg/5g), oral suspension 
(40mg/ml), oral tablets/pills (250mg or 400mg) and parenteral 
solution (0.5%). Topical formulations have high concentration 
because the amount of cream/ointment applied is small, about 
5 to 10g in the treatment of vaginitis or acne rosacea.
Two Brazilian oncology hospitals report using pills di-
luted in saline solution at bedside in their protocols for odor 
control of neoplastic wounds; and silver and papain are used 
for odor control of other etiologies(21).
Because there are no ready-made metronidazole 0.8% 
topical formulations, manipulation becomes necessary – for 
example metronidazole tablets associated to physiological 
saline solution (off-label use)(22-23).
CONCLUSION
Based on the results of this systematic review, the met-
ronidazole solution is recommended in clinical practice to 
control odor in infected wounds, and used more appropri-
ately in malignant neoplastic wounds, but there are no ran-
domized controlled trials of strong evidence to effectively 
support this. Other clinical studies of stronger evidence 
should be performed so we can use off-label metronidazole 
more assertively and clinically safe.
RESUMO
Objetivo: Verificar as evidências da aplicação tópica de metronidazol na eficácia terapêutica para controle de odor de feridas. Método: 
Revisão sistemática de literatura, segundo as recomendações da Cochrane Collaboration. Resultados: Identificaram-se 329 artigos nas 
bases de dados Cochrane, LILACS, ScIELO, Cinahl e PubMed, incluindo-se 14 deles na amostra final. Desses, dois estudos são do tipo 
ensaio clínico, randomizado e duplo-cego. Conclusão: Devido à ausência de estudos de forte evidência sobre a eficácia do metronidazol 
no controle de odor em feridas, ainda não se pode evidenciar a sua real eficácia para tal objetivo, apesar da prática clínica recomendar 
seus benefícios.
DESCRITORES
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RESUMEN
Objetivo: Verifying the evidence of therapeutic efficacy in the topical application of metronidazole for controlling wound odor. 
Methods: A systematic literature review, according to the Cochrane Collaboration recommendations. Results: 329 articles were identified 
in the Cochrane, LILACS, SciELO, CINAHL and PubMed databases, with 14 of them being included in the final sample. Two of the 
studies were double-blind randomized clinical trial studies. Conclusion: The actual effectiveness of metronidazole in controlling wound 
odor cannot yet be evidenced due to the absence of strong evidence from studies on the subject, despite clinical practice recommending 
its benefits.
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Wounds and Injuries; Deodorization; Metronidazole; Wound Infection; Review.
REFERENCES
1. Sarabahi S. Recent advances in topical wound care. Indian J Plast Surg. 2012;45(2):379-87.
2. Bale S, Tebbie N, Prince P. A topical metronidazole gel used to treat malodorous wounds. Br J Nurs. 2004;13(11):S4-11.
3. Morris C. Wound odour: principles of management and the use of Clinisorb. Br J Nurs. 2008; 17(6):S38-42.
4. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. London: 
The Cochrane Collaboration; 2011.
5. Malta M, Cardoso LO, Bastos FI, Magnanini MMF, Silva CMFP. STROBE initiative: guidelines on reporting observational studies. Rev Saúde 
Pública [Internet]. 2010 [cited 2014 Oct 12];44(3):559-65. Available from: http://www.scielo.br/pdf/rsp/v44n3/en_21.pdf
6. Altman DG, Schultz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: 
explanation and elaboration. Ann Intern Med. 2001;134(8):663-94.
7. Jones PH, Willis AT, Ferguson IR. Treatment of anaerobically infected pressure sores with topical metronidazole. Lancet. 1978;1(8057):213-
4.
8. Ashford R, Plant G, Maher J, Teare L. Double-blind trial of metronidazole in malodorous ulcerating tumours. Lancet. 1984;1(8388):1232-3.
9. Ashford RFU, Plant GT, Maher J, Pickering D, Coe MA, Drury A, et al. Metronidazole in smelly tumors. Lancet. 1980;1(8173):874-5.
856 Rev Esc Enferm USP · 2015; 49(5):851-856 www.ee.usp.br/reeusp
Controlling wound odor with metronidazole: a systematic review
10. Gomolin IH, Brandt JL. Topical metronidazole therapy for pressure sores of geriatric patients. J Am Geriatr Soc. 1983;31(11):710-2.
11. Pierleoni EE. Topical metronidazole therapy for infected decubitus ulcers. J Am Geriatr Soc. 1984;32(10):775.
12. Burnakis TG. Topical metronidazole for decubitus ulcers. Hosp Pharm. 1989;24(11):960-1.
13. Witkowski JA, Parish LC. Topical metronidazole gel: the bacteriology of decubitus ulcers. Int J Dermatol. 1991;30(9):660-1.
14. McMullen D. Topical metronidazole. Part II. Ostomy Wound Manage. 1992;38(3):42-6, 48.
15. Newman V, Allwood M, Oakes RA. The use of metronidazole gel to control the smell of malodours lesions. Palliat Med. 1989;3(4):303-5.
16. Bower M, Stein R, Evans TR, Hedley A, Coombes RC. A doble-blind study of the efficacy of metronidazole gel in the treatment of 
malodorous fungating tumours. Eur J Cancer. 1992;28A(4-5):888-9.
17. Finlay IG, Bowszyc J, Ramlau C, Gwiezdzinski Z. The effect of topical 0,75% metronidazole gel on malodours cutaneous ulcers. J Pain 
Symptom Manage. 1996;11(3):158-62.
18. Kuge S, Tokuda Y, Ohta M, Okumura A, Kubota M, Ninomiya S, et al. Use of metronidazole gel to control malodor in advanced recurrent 
breast cancer. Jpn J Clin Oncol. 1996;26(4): 207-10.
19. Kalinski C, Schnepf M, Laboy D, Hernandez L, Nusbaum J, McGrinder B, et al. Effectiveness of topical formulation containing metronidazole 
for wound odor and exudate control. Wounds. 2005;17(4):84-9.
20. Finegold SM. Anaerobic infections in humans: an overview. Anaerobe. 1995;1(1):3-9.
21. Matsubara MGS, Villela DL, Hashimoto SY, Silva Reis HC, Saconato RA, Denardi UA, et al. Feridas e estomas em oncologia: uma 
abordagem interdisciplinar. São Paulo: Lemar; 2011.
22. Brasil. Ministério da Saúde; Secretaria de Ciências, Tecnologias e Insumos estratégicos, Comissão Nacional de Incorporação de Tecnologias 
no SUS. Uso off label: erro ou necessidade? Rev Saúde Pública. 2012;46(2):398-9.
23. Brasil. Ministério da Saúde; Agência Nacional de Vigilância Sanitária (ANVISA). Como a ANVISA vê o uso off label de medicamentos 
[Internet]. Brasília; 2005 [citado 2014 out. 12]. Disponível em: http//www.anvisa.gov.br/medicamentos/registro/registro_offlabel.htm
